4.6 Article

Acute chest syndrome in adult patients with sickle cell disease: The relationship with the time to onset after hospital admission

期刊

BRITISH JOURNAL OF HAEMATOLOGY
卷 201, 期 6, 页码 1229-1238

出版社

WILEY
DOI: 10.1111/bjh.18777

关键词

acute chest syndrome; bronchial breathing; chest pain; respiratory rate

向作者/读者索取更多资源

This study describes 105 cases of acute chest syndrome (ACS) in 81 adult patients with sickle cell disease over a 32-month period. The characteristics of ACS episodes were compared based on time to onset after hospital admission for vaso-occlusive crisis (VOC). The early-onset episodes (<= 24h) accounted for 42% and secondary episodes (>24h) accounted for 58%. Fever and chest pain were the main symptoms, and crackles and bronchial breathing were the main abnormal findings. Disease-modifying treatments should be reevaluated after each ACS episode due to the high recurrence rate.
Data on acute chest syndrome (ACS) in adult sickle cell disease patients are scarce. In this study, we describe 105 consecutive ACS episodes in 81 adult patients during a 32-month period and compare the characteristics as a function of the time to onset after hospital admission for a vaso-occlusive crisis (VOC), that is early-onset episodes (time to onset <= 24 h, 42%) versus secondary episodes (>24 h, 58%; median [interquartile range] time to onset: 2 [2-3] days). The median age was 27 [22-34] years, 89% of the patients had an S/S or S/b(0)-thalassaemia genotype; 81% of the patients had a history of ACS (median: 3 [2-5] per patient), only 61% were taking a disease-modifying treatment at the time of the ACS. Fever and chest pain were noted in respectively 54% and 73% of the episodes. Crackles (64%) and bronchial breathing (32%) were the main abnormal auscultatory findings. A positive microbiological test was found for 20% of episodes. Fifty percent of the episodes required a blood transfusion; ICU transfer and mortality rates were respectively 29% and 1%. Secondary and early-onset forms of ACS did not differ significantly. Disease-modifying treatments should be revaluated after each ACS episode because the recurrence rate is high.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据